CDK4 and cancer: Moreover, the observation that cancer patients treated with CDK4/6 could have increased death rates due to the development of atrial fibrillation/atrial flutter or heart failure, raises some concerns for their use in cardiovascular disease and suggests that further research is needed to determine cardiovascular risks associated with the use of CDKs inhibitors in clinic.501